PhoenixBio Co., Ltd. (JP:6190)
:6190
6190 Stock Chart & Stats
¥484.00
¥9.00(2.79%)
At close: 4:00 PM EST
¥484.00
¥9.00(2.79%)
Day’s Range― - ―
52-Week Range¥252.00 - ¥724.00
Previous CloseN/A
Volume3.50K
Average Volume (3M)360.67K
Market Cap
¥1.90B
Enterprise Value¥1.28B
Total Cash (Recent Filing)¥1.04B
Total Debt (Recent Filing)¥503.59M
Price to Earnings (P/E)6.1
Beta0.52
Next Earnings
May 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)19.91
Shares Outstanding4,076,933
10 Day Avg. Volume91,460
30 Day Avg. Volume360,670
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.09
Price to Sales (P/S)0.97
P/FCF Ratio-15.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Humanized Model PlatformPhoenixBio's proprietary PXB-mice platform is a durable competitive asset in preclinical drug discovery. High scientific know‑how, biological materials and specialized protocols create high barriers to entry, supporting recurring demand from pharma customers and long‑term licensing and service revenue.
Multiple Revenue StreamsA mix of product sales, licensing/usage fees and fee‑for‑service studies diversifies revenue drivers and reduces single‑channel dependence. This structural mix supports steadier revenue capture as platform adoption grows and allows the business to monetize both materials and higher‑margin services over time.
Relatively Healthy Balance SheetA stable equity base and moderate leverage give PhoenixBio financial flexibility to fund operations, maintain the platform and invest in service capacity without immediate reliance on dilutive equity or expensive debt. This stability helps absorb biotech cycle volatility over the medium term.
Bears Say
Negative Operating Cash FlowPersistent negative operating and free cash flow constrains PhoenixBio's ability to self‑fund platform maintenance and study capacity. Over 2–6 months this raises the likelihood of needing external financing, which can dilute shareholders or increase leverage and limit strategic investments.
Negative Profitability And MarginsOngoing negative operating margins point to either pricing or cost structure issues. Without margin recovery, the company will struggle to translate platform demand into sustainable profits, limiting reinvestment capacity and long‑term value creation for investors over the medium term.
Declining Revenues And Asset BaseDeclining revenues alongside a shrinking asset base signal weakening scale or reduced customer activity. This structural trend undermines economies of scale for the platform, risks higher per‑unit costs and exacerbates cash burn, making durable recovery more difficult without strategic intervention.
6190 FAQ
What was PhoenixBio Co., Ltd.’s price range in the past 12 months?
PhoenixBio Co., Ltd. lowest stock price was ¥252.00 and its highest was ¥724.00 in the past 12 months.
What is PhoenixBio Co., Ltd.’s market cap?
PhoenixBio Co., Ltd.’s market cap is ¥1.90B.
When is PhoenixBio Co., Ltd.’s upcoming earnings report date?
PhoenixBio Co., Ltd.’s upcoming earnings report date is May 15, 2026 which is in 37 days.
How were PhoenixBio Co., Ltd.’s earnings last quarter?
PhoenixBio Co., Ltd. released its earnings results on Feb 13, 2026. The company reported ¥19.91 earnings per share for the quarter, beating the consensus estimate of N/A by ¥19.91.
Is PhoenixBio Co., Ltd. overvalued?
According to Wall Street analysts PhoenixBio Co., Ltd.’s price is currently Overvalued.
Does PhoenixBio Co., Ltd. pay dividends?
PhoenixBio Co., Ltd. does not currently pay dividends.
What is PhoenixBio Co., Ltd.’s EPS estimate?
PhoenixBio Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PhoenixBio Co., Ltd. have?
PhoenixBio Co., Ltd. has 4,076,933 shares outstanding.
What happened to PhoenixBio Co., Ltd.’s price movement after its last earnings report?
PhoenixBio Co., Ltd. reported an EPS of ¥19.91 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.112%.
Which hedge fund is a major shareholder of PhoenixBio Co., Ltd.?
Currently, no hedge funds are holding shares in JP:6190
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PhoenixBio Co., Ltd.
PhoenixBio Co., Ltd. provides contract study services for drug discovery and development primarily in Japan. The company uses PXB-mouse, a chimeric mouse with a humanized liver for use in drug development experiments; and in vitro studies using fresh human hepatocytes taken from PXB-cells. The chimeric mouse model with a humanized liver is used for in vivo studies in gene therapeutics, NASH/NAFLD drug development programs, anti-viral therapeutic tests, DMPK/toxicity studies, and custom transplantations. The company was founded in 2002 and is headquartered in Higashihiroshima, Japan.
Technical Analysis
Trans Genic Inc.
―
Takara Bio Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―